Literature DB >> 32970346

What happened to the US cancer cooperative groups? A status update ten years after the Institute of Medicine report.

Monica M Bertagnolli1, Charles D Blanke2, Walter J Curran3, Douglas S Hawkins4, Robert S Mannel5, Peter J O'Dwyer6, Mitchell D Schnall7, Norman Wolmark8.   

Abstract

The US cancer cooperative groups (cooperative groups) were founded in the 1950s to establish a standing infrastructure to conduct multi-institutional cancer clinical trials. Initially funded almost entirely by the US National Cancer Institute (NCI), over the years, the research conducted by the Cooperative Groups has evolved to meet the demands of cancer clinical research, with a scope now encompassing trials to advance cancer treatment, cancer control, biomarker development and validation, and health services research, with a corresponding broadening of their funding sources. The cooperative groups are also a critical mechanism for educating the next generation of cancer clinical trialists from many different disciplines. This review outlines the overall mission, structure, and funding of the cooperative groups, beginning in 1955 when they were first established by the NCI, and describes the considerable progress against cancer achieved over the past decade.
© 2020 American Cancer Society.

Entities:  

Keywords:  NCI Community Oncology Research Program (NCORP); NCI National Clinical Trials Network (NCTN); National Cancer Institute (NCI); cancer clinical trials; cooperative groups

Mesh:

Year:  2020        PMID: 32970346      PMCID: PMC7667615          DOI: 10.1002/cncr.33209

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  A comparative study of two regimens of combination chemotherapy in acute leukemia.

Authors:  E FREI; J F HOLLAND; M A SCHNEIDERMAN; D PINKEL; G SELKIRK; E J FREIREICH; R T SILVER; G L GOLD; W REGELSON
Journal:  Blood       Date:  1958-12       Impact factor: 22.113

2.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

Authors:  Soonmyung Paik; Steven Shak; Gong Tang; Chungyeul Kim; Joffre Baker; Maureen Cronin; Frederick L Baehner; Michael G Walker; Drew Watson; Taesung Park; William Hiller; Edwin R Fisher; D Lawrence Wickerham; John Bryant; Norman Wolmark
Journal:  N Engl J Med       Date:  2004-12-10       Impact factor: 91.245

Review 3.  A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics: A Review.

Authors:  Julia A Beaver; Lynn J Howie; Lorraine Pelosof; Tamy Kim; Jinzhong Liu; Kirsten B Goldberg; Rajeshwari Sridhara; Gideon M Blumenthal; Ann T Farrell; Patricia Keegan; Richard Pazdur; Paul G Kluetz
Journal:  JAMA Oncol       Date:  2018-06-01       Impact factor: 31.777

4.  Reduced lung-cancer mortality with low-dose computed tomographic screening.

Authors:  Denise R Aberle; Amanda M Adams; Christine D Berg; William C Black; Jonathan D Clapp; Richard M Fagerstrom; Ilana F Gareen; Constantine Gatsonis; Pamela M Marcus; JoRean D Sicks
Journal:  N Engl J Med       Date:  2011-06-29       Impact factor: 91.245

5.  The occurrence of rare cancers in U.S. adults, 1995-2004.

Authors:  Robert T Greenlee; Marc T Goodman; Charles F Lynch; Charles E Platz; Lori A Havener; Holly L Howe
Journal:  Public Health Rep       Date:  2010 Jan-Feb       Impact factor: 2.792

Review 6.  A concise history of the cancer and leukemia group B.

Authors:  Richard L Schilsky; O Ross McIntyre; James F Holland; Emil Frei
Journal:  Clin Cancer Res       Date:  2006-06-01       Impact factor: 12.531

7.  A Southwest Oncology Group study on the use of a human tumor cloning assay for predicting response in patients with ovarian cancer.

Authors:  D D Von Hoff; R Kronmal; S E Salmon; J Turner; J B Green; J S Bonorris; E L Moorhead; H E Hynes; R E Pugh; R J Belt
Journal:  Cancer       Date:  1991-01-01       Impact factor: 6.860

Review 8.  Landmark trials affecting the surgical management of invasive breast cancer.

Authors:  Dalliah M Black; Elizabeth A Mittendorf
Journal:  Surg Clin North Am       Date:  2013-01-29       Impact factor: 2.741

9.  Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.

Authors:  Joseph A Sparano; Robert J Gray; Della F Makower; Kathleen I Pritchard; Kathy S Albain; Daniel F Hayes; Charles E Geyer; Elizabeth C Dees; Matthew P Goetz; John A Olson; Tracy Lively; Sunil S Badve; Thomas J Saphner; Lynne I Wagner; Timothy J Whelan; Matthew J Ellis; Soonmyung Paik; William C Wood; Peter M Ravdin; Maccon M Keane; Henry L Gomez Moreno; Pavan S Reddy; Timothy F Goggins; Ingrid A Mayer; Adam M Brufsky; Deborah L Toppmeyer; Virginia G Kaklamani; Jeffrey L Berenberg; Jeffrey Abrams; George W Sledge
Journal:  N Engl J Med       Date:  2018-06-03       Impact factor: 91.245

Review 10.  An overview of precision oncology basket and umbrella trials for clinicians.

Authors:  Jay J H Park; Grace Hsu; Ellie G Siden; Kristian Thorlund; Edward J Mills
Journal:  CA Cancer J Clin       Date:  2020-02-07       Impact factor: 508.702

  10 in total
  3 in total

1.  Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials.

Authors:  Shubham Sharma; J Connor Wells; Wilma M Hopman; Joseph C Del Paggio; Bishal Gyawali; Nazik Hammad; Annette E Hay; Christopher M Booth
Journal:  Curr Oncol       Date:  2021-04-13       Impact factor: 3.677

Review 2.  Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement.

Authors:  Stephen J Bagley; Shawn Kothari; Rifaquat Rahman; Eudocia Q Lee; Gavin P Dunn; Evanthia Galanis; Susan M Chang; Louis Burt Nabors; Manmeet S Ahluwalia; Roger Stupp; Minesh P Mehta; David A Reardon; Stuart A Grossman; Erik P Sulman; John H Sampson; Simon Khagi; Michael Weller; Timothy F Cloughesy; Patrick Y Wen; Mustafa Khasraw
Journal:  Clin Cancer Res       Date:  2022-02-15       Impact factor: 13.801

3.  Creating and Implementing a Principal Investigator Tool Kit for Enhancing Accrual to Late Phase Clinical Trials: Development and Usability Study.

Authors:  Alexandra Thomas; Kristin A Higgins; Nancy Soto; Rebecca Paulus; Thomas J George; Thomas B Julian; Sharon Hartson Stine; Merry Jennifer Markham; Maria Werner-Wasik
Journal:  JMIR Cancer       Date:  2022-08-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.